ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Historical Holders from Q4 2014 to Q1 2025

Symbol
ARWR on Nasdaq
CUSIP
04280A100
Type / Class
Equity / Common stock, par value $0.001 per share (the "Common Stock")
Shares outstanding
126M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
99.7M
Holdings value
$1.87B
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
268
Number of buys
119
Number of sells
-125
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Avoro Capital Advisors LLC 9.6% $181M 12M Avoro Capital Advisors LLC Dec 31, 2024
Sarepta Therapeutics, Inc. 9.5% $180M 11.9M Sarepta Therapeutics, Inc. Feb 7, 2025
STATE STREET CORP 4.8% $90.7M 6.02M STATE STREET CORPORATION Dec 31, 2024

Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 748K $9.53M +$945K $12.74 26
2024 Q4 99.7M $1.87B +$70.6M $18.80 268
2024 Q3 95.7M $1.85B -$144M $19.37 269
2024 Q2 97.8M $2.54B +$100M $25.99 272
2024 Q1 95M $2.72B +$481M $28.60 270
2023 Q4 76.5M $2.34B +$118M $30.60 263
2023 Q3 73.5M $1.97B +$40.1M $26.87 249
2023 Q2 70.6M $2.52B -$38.5M $35.66 265
2023 Q1 72.9M $1.85B -$22.3M $25.40 249
2022 Q4 73.2M $2.97B +$98.1M $40.56 272
2022 Q3 70.1M $2.31B -$35.8M $33.05 259
2022 Q2 69.3M $2.44B +$115M $35.21 259
2022 Q1 67M $3.08B +$25.6M $45.99 287
2021 Q4 67.7M $4.49B +$59.7M $66.30 294
2021 Q3 65.9M $4.12B -$72.9M $62.43 283
2021 Q2 66.4M $5.49B -$133M $82.82 304
2021 Q1 67.9M $4.51B -$34M $66.31 281
2020 Q4 65.6M $5.04B +$76.2M $76.73 297
2020 Q3 68M $2.93B -$16.1M $43.06 250
2020 Q2 68.6M $2.96B +$127M $43.19 236
2020 Q1 65.4M $1.88B -$60.9M $28.77 225
2019 Q4 64.8M $4.11B -$251M $63.43 283
2019 Q3 65.5M $1.84B -$64.7M $28.18 213
2019 Q2 68.2M $1.81B +$469M $26.50 206
2019 Q1 58.9M $1.08B +$8M $18.35 172
2018 Q4 58.3M $724M -$833K $12.42 155
2018 Q3 54.7M $1.05B +$86.9M $19.17 129
2018 Q2 51.7M $703M +$175M $13.60 112
2018 Q1 40.7M $293M +$131M $7.21 88
2017 Q4 23.4M $85.9M +$30.3M $3.68 73
2017 Q3 15M $64.9M +$4.08M $4.33 54
2017 Q2 15.4M $24.9M -$15.5M $1.62 49
2017 Q1 24.3M $45M +$7.66M $1.85 76
2016 Q4 25.3M $39.2M -$54.6M $1.55 75
2016 Q3 30.1M $221M +$70.6M $7.35 93
2016 Q2 20.6M $110M +$97.6M $5.32 84
2016 Q1 2.13M $10.3M +$10.3M $4.82 6
2015 Q4 500 $4K $0 $8.00 1
2015 Q3 500 $3K $0 $6.00 1
2015 Q2 500 $4K $0 $8.00 1
2015 Q1 500 $4K $0 $8.00 1
2014 Q4 500 $4K $0 $8.00 1